Real-life data of etanercept efficacy and safety in juvenile idiopathic arthritis: a 24-month retrospective study at a single center

ABSTRACT

Objective

The aim of this study was to assess the efficacy and safety of etanercept (ETA) use in juvenile idiopathic arthritis (JIA).

Methods

The 24-month data of patients with JIA on etanercept in a single center were evaluated retrospectively. Response to treatment was assessed according to 10-joint Juvenile Arthritis Disease Activity Score (JADAS10), and JIA-American College of Rheumatology (ACR) improvement criteria. Safety assessments were based on adverse event (AE) reports.

Results

The study included 152 patients with JIA. The mean age at diagnosis of JIA was 8.5 ± 4.4 years, and treatment with ETA started at a mean age of 11.1 ± 4.4 years. The mean duration of ETA use was 16 ± 11.1 months. The mean JADAS10 score at baseline was 18.5 ± 5.9. By the third month, it had reduced to 8.6 ± 6.6 and by the sixth month to 5.7 ± 6. By the twelfth month, the JADAS10 score was 4.9 ± 6.7, and by the twenty-fourth month, it worsened to 7.3 ± 7.8. ACR50 response, was achieved in 79.6% of patients at three months, 67.1% at six months, 79.3% at twelfth months, 70.7% at twenty-fourth months. During ETA treatment, 10 patients required hospitalization for serious infections.

Conclusion

Etanercept is a safe and effective option for patients with JIA. However, variations in response between JIA subtypes highlight the need for individualized treatment strategies.

KEYWORDS:

• Etanercept
• juvenile idiopathic arthritis
• Anti-TNF therapy
• JADAS10
• ACR response

Disclaimer

As a service to authors and researchers we are providing this version of an accepted manuscript (AM). Copyediting, typesetting, and review of the resulting proofs will be undertaken on this manuscript before final publication of the Version of Record (VoR). During production and pre-press, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal relate to these versions also.

Declaration of interest

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Reviewer disclosures

Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

Author contributions

B Sözeri contributed to the study conception and design. RE Yiğit and K Ulu contributed to data collection. All authors conducted the data analysis. All authors were involved in interpretation of the data and the writing and critical review of the manuscript. All authors and read and approved the final manuscript.

Data availability statement

The data and materials from this study can be made available on reasonable request.

Ethics statement

The study was approved by the local ethics committee of Umraniye Training and Research Hospital and was conducted in accordance with the tenets of the Declaration of Helsinki. Written informed consent was obtained from the legal guardians of the children.

Additional information

Funding

This paper was not funded.